PEDIATRIC ONCOLOGY GROUP PROGRAM

随着有关肿瘤性质的新数据几乎呈爆炸性发展 生物，合作团体在可预见的未来的使命 变得越来越具有挑战性和复杂性。关于肿瘤的信息 生物学必须融入到可行的群体意志的发展中 和组内II/III期研究。因此，设计的协议 急性淋巴细胞性白血病的特定亚群必须解决T细胞 和B细胞亚型，并继续深入研究前B细胞和 前T亚型。在急性髓细胞白血病中，必须努力识别风险因素 同时利用最佳可用“标准”疗法的随机试验。 在这方面，必须努力评估已证实的 利用(1)药物-药物相互作用，(2)疗效的新知识进行治疗 大剂量或大剂量治疗，以及(3)“净化”技术的作用。 例如(1)包括甲氨蝶呤-天冬酰胺酶，(2)高剂量胞嘧啶 阿拉伯糖苷；(3)抗体清除。骨髓移植作为一种 主要的治疗臂值得深入评估。伊利诺伊大学 佛罗里达州为第二轮制定了最有利的准备方案 全部减免，作为8个机构POG研究的一部分，它将 现在适用于首次缓解所有高危人群。一份关于骨髓的建议 第二次缓解的急性髓细胞白血病的移植现在可供团体使用，以及 骨髓移植正在进行中，用于治疗高危神经母细胞瘤 在当地试行霍奇金氏病、尤因肉瘤和 非霍奇金淋巴瘤。抗体包被的骨髓净化技术 针对神经母细胞瘤的磁化微球，CALLA(+)，ALL和 所有的T细胞都在当地进行。佛罗里达大学骨髓分校 移植单位也是多机构慢性粒细胞白血病的组成部分 移植研究。除了在整个团队中积极参与 努力，正在进行的药理学和药代动力学计划将 继续设计方案，以解决有利的用法 化疗药物的种类。最后，这个部门扩大了它的 包括杰克逊维尔大学医院在内的计划已提交 增加了癌症控制机构，并扩大了其范围 遗传学和长期效应的研究。

With the almost explosive evolution of new data on the nature of tumor biology, the mandate for cooperative groups in the forseeable future becomes increasingly more challenging and complex. Information on tumor biology must be incorporated into the development of feasible group-will and intra(sub) group phase II/III studies. As a result, protocols designed for specific subgroups in acute lymphoblastic leukemia must address T-cell and B-cell subtypes and continue to delve into the nature of pre-B and pre-T subtypes. In AML, efforts must be made to identify risk factors whilst utilizing randomized trials of best available "standard" therapy. In this regard, efforts must be made to evaluate new combinations of proven therapy utilizing new knowledge of (1) drug-drug interaction, (2) efficacy of high or mega-dose therapy, and (3) the role of "cleansing" techniques. Examples of (1) include methotrexate-asparaginase, (2) high dose cytosine arabinoside, and (3) antibody purging. Bone marrow transplantation as a major therapeutic arm deserves intensive evaluation. The University of Florida has developed a most favorable preparative regimen for second remission ALL, as part of an 8 institution POG study which, which it will now apply to first remission high risk ALL. A proposal for marrow transplantation in second remission AML is now available for group use, and bone marrow transplantation is underway in high risk neuroblastoma, and is being piloted locally in Hodgkin's disease, Ewing's sarcoma and non-Hodgkin's lymphoma. Bone marrow cleansing with antibody coated magnetized microspheres directed against neuroblastoma, cALLa(+), ALL and T-cell ALL are underway locally. The University of Florida Bone Marrow Transplantation Unit is also a component of a multi-institution CML transplantation study. In addition to active participation in whole group efforts, ongoing programs in pharmacology and pharmacokinetics will continue in order to design regimens which will address the propitious use of chemotherapeutic agents. Finally, this division has expanded its program to include University Hospital of Jacksonville, has submitted additional institutions for cancer control and has broadened its range of studies in genetics and long term effects.